APRA (aprA / PA1249) — Pseudomonas aeruginosa alkaline metalloprotease (Serralysin)

UniProt: Q03023 (APRA_PSEAE); EC 3.4.24.40; MEROPS M10.056; peptidase M10B
(serralysin) family. 479 aa precursor (propeptide 1–9, mature chain 10–479).

Summary

AprA is a secreted, zinc-dependent alkaline metalloendopeptidase of the
serralysin (RTX-type metalloprotease, peptidase M10B) family. It is a major
extracellular virulence factor of P. aeruginosa. Structurally it is a
two-domain protein: an N-terminal catalytic metallopeptidase domain (HEXXH zinc
motif) and a C-terminal β-roll domain formed by hemolysin-type (RTX)
calcium-binding repeats that bind multiple Ca²⁺ ions. It has no cleavable
N-terminal signal peptide and is exported by a dedicated type I secretion system
(the AprDEF ABC-transporter / RTX exporter encoded in the same operon), with a
C-terminal secretion signal. It is co-secreted with, and held in check by, the
periplasmic/secreted inhibitor AprI.

Catalytically it preferentially cleaves peptide bonds N-terminal to (in P1' of)
hydrophobic residues. Biologically it acts on a broad range of host substrates,
and its best-characterized roles are in innate-immune evasion and modulation of
host epithelial physiology.

Structure / cofactors (from UniProt Q03023 + crystallography)

Catalytic activity / specificity

Biological roles / host substrates (virulence)

1. Innate-immune evasion via degradation of monomeric flagellin (TLR5/FLS2)

2. Inhibition of complement (classical + lectin pathways) via C2 cleavage

3. Activation of the epithelial sodium channel (ENaC)

GO annotation review orientation

Core function:
- Molecular function: zinc metalloendopeptidase activity (GO:0004222), with
catalytic Zn²⁺ binding (GO:0008270) and structural Ca²⁺ binding (GO:0005509).
- Cellular component: secreted / extracellular region (GO:0005576;
GO:0005615 extracellular space is the more precise term).
- Biological process: proteolysis (GO:0006508), executed on host substrates
to drive virulence (immune evasion; host ion-transport modulation = non-core,
pleiotropic downstream consequences).

Likely over-/under-annotations to flag:
- GO:0008233 (peptidase) and GO:0008237 (metallopeptidase) IEA are correct but are
high-level parents of the more informative GO:0004222 metalloendopeptidase
activity → general/redundant.
- GO:0031012 "extracellular matrix" (located_in, IEA from InterPro) is a likely
over-annotation — AprA is freely secreted into the extracellular space, not a
structural ECM component. Prefer GO:0005576 / GO:0005615.

Additional findings (from falcon/Edison deep research, APRA-deep-research-falcon.md)

Broader experimentally/review-supported substrate range and roles (not all yet GO-annotated):
- Complement: primary substrate is C2 (cleaved into C2a/C2b, ~200 nM, blocks
C4b2a convertase); also degrades C1q, C1s, C3, C5a. "AprA was identified as
the first bacterial protease demonstrated to cleave C2."
- Cytokines: degrades IFN-γ and TNF-α, dampening inflammatory signaling.
- Disrupts neutrophil extracellular traps (NETs).
- Corneal infection: degrades fibrin, causes tissue necrosis, increases
bacterial attachment to corneal epithelium.
- Polymicrobial biofilm: cleaves S. aureus surface protein SasG (removes
A domain, exposes B domain → MRSA aggregation, biofilm, antibiotic tolerance)
[keim2024, bioRxiv preprint — treat as provisional].
- Virulence in vivo: aprA deletion raised murine survival to 77% vs 33% for
WT PAO1 (cutaneous infection), with no change in bacterial counts [pletzer2020].
- Secretion: type I secretion system encoded by the aprDEF operon (AprD ABC
transporter, AprE membrane-fusion protein, AprF outer-membrane factor); secreted
with propeptide intact; folding/activation is Ca²⁺-dependent (RTX β-roll).
- Regulation: Las/Rhl quorum sensing and the ppGpp stringent response.
- Conservation: apr gene present in ~99% of clinical P. aeruginosa isolates;
proposed anti-virulence drug target.

Note: the falcon report mis-attributes the flagellin/TLR5 finding to Laarman 2012;
the correct primary source is Bardoel 2011 (PMID:21901099).

References